DK1173434T3 - Thiazolidindionderivat og dets anvendelse som antidiabetisk middel - Google Patents

Thiazolidindionderivat og dets anvendelse som antidiabetisk middel

Info

Publication number
DK1173434T3
DK1173434T3 DK00920889T DK00920889T DK1173434T3 DK 1173434 T3 DK1173434 T3 DK 1173434T3 DK 00920889 T DK00920889 T DK 00920889T DK 00920889 T DK00920889 T DK 00920889T DK 1173434 T3 DK1173434 T3 DK 1173434T3
Authority
DK
Denmark
Prior art keywords
antidiabetic agent
thiazolidinedione derivative
thiazolidinedione
derivative
antidiabetic
Prior art date
Application number
DK00920889T
Other languages
Danish (da)
English (en)
Inventor
Paul D J Blackler
Robert Gordon Giles
Michael John Sasse
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1173434(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9909472.4A external-priority patent/GB9909472D0/en
Priority claimed from GBGB9912197.2A external-priority patent/GB9912197D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DK1173434T3 publication Critical patent/DK1173434T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)
DK00920889T 1999-04-23 2000-04-19 Thiazolidindionderivat og dets anvendelse som antidiabetisk middel DK1173434T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9909472.4A GB9909472D0 (en) 1999-04-23 1999-04-23 Novel compounds
GBGB9912197.2A GB9912197D0 (en) 1999-05-25 1999-05-25 Novel pharmaceutical
PCT/GB2000/001514 WO2000064892A2 (en) 1999-04-23 2000-04-19 Thiazolidinedione derivative and its use as antidiabetic

Publications (1)

Publication Number Publication Date
DK1173434T3 true DK1173434T3 (da) 2003-12-08

Family

ID=26315460

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00920889T DK1173434T3 (da) 1999-04-23 2000-04-19 Thiazolidindionderivat og dets anvendelse som antidiabetisk middel
DK02080320T DK1284268T3 (da) 1999-04-23 2000-04-19 Fremstilling af en polymorf form af et thiazolidindionderivat

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02080320T DK1284268T3 (da) 1999-04-23 2000-04-19 Fremstilling af en polymorf form af et thiazolidindionderivat

Country Status (40)

Country Link
US (2) US6815457B1 (de)
EP (3) EP1903043A1 (de)
JP (1) JP2002543075A (de)
KR (1) KR100744359B1 (de)
CN (1) CN1208335C (de)
AP (1) AP1495A (de)
AR (2) AR023564A1 (de)
AT (2) ATE382046T1 (de)
AU (1) AU765498B2 (de)
BG (1) BG65427B1 (de)
BR (1) BR0009934A (de)
CA (1) CA2370258A1 (de)
CO (1) CO5170424A1 (de)
CY (1) CY1107238T1 (de)
CZ (1) CZ20013799A3 (de)
DE (2) DE60004658T2 (de)
DK (2) DK1173434T3 (de)
DZ (1) DZ3155A1 (de)
EA (1) EA004534B1 (de)
ES (2) ES2298327T3 (de)
HK (2) HK1045154B (de)
HR (1) HRP20010773B1 (de)
HU (1) HUP0200929A3 (de)
IL (1) IL146110A0 (de)
MA (1) MA26785A1 (de)
MX (1) MXPA01010820A (de)
MY (1) MY128007A (de)
NO (1) NO320589B1 (de)
NZ (1) NZ515163A (de)
OA (1) OA11871A (de)
PE (1) PE20010040A1 (de)
PL (1) PL351686A1 (de)
PT (2) PT1284268E (de)
RS (1) RS50114B (de)
SK (1) SK286423B6 (de)
TR (1) TR200103061T2 (de)
TW (1) TW591027B (de)
UA (1) UA67843C2 (de)
UY (1) UY26120A1 (de)
WO (1) WO2000064892A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
DK1173434T3 (da) 1999-04-23 2003-12-08 Smithkline Beecham Plc Thiazolidindionderivat og dets anvendelse som antidiabetisk middel
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
PE20010044A1 (es) * 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
IL155036A0 (en) * 2000-09-26 2003-10-31 Reddy Research Foundation Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] benzyl] thiazolidine-2,4-dione maleate and pharmaceutical compositions containing the same
US7241895B2 (en) * 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
WO2003050116A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
AU2002352479A1 (en) * 2001-12-20 2003-07-09 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1468997A3 (de) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphe Formen von Rosiglitazon Maleat
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
EP1709038A2 (de) * 2004-01-28 2006-10-11 Usv Limited Verfahren zur herstellung von 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]phenylmethyl]thiazolidin-2,4-dionmaleat
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
EP2184055A1 (de) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Verfahren zur Herstellung fester Dosierungsformen von Rosiglitazonmaleat

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
ATE186724T1 (de) 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB9124513D0 (en) 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US20010044458A1 (en) * 1994-02-10 2001-11-22 Smithkline Beechamp P.L.C. Use of insulin sensitisers for treating renal diseases
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
SG47100A1 (en) 1994-02-10 1998-03-20 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
GB9711683D0 (en) 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
US20020028768A1 (en) * 1997-06-18 2002-03-07 Smithkline Beecham P.L.C. Treatment of diabetes with rosiglitazone and insulin
KR20010013845A (ko) 1997-06-18 2001-02-26 피터 기딩스 티아졸리딘디온 및 알파-글루코시다제 억제제를 사용한당뇨병의 치료
WO1998057649A1 (en) 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
ATE355840T1 (de) 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9712866D0 (en) 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
US20020045649A1 (en) * 1997-07-18 2002-04-18 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726566D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
PE20010044A1 (es) 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
DK1173434T3 (da) 1999-04-23 2003-12-08 Smithkline Beecham Plc Thiazolidindionderivat og dets anvendelse som antidiabetisk middel
WO2000064893A2 (en) 1999-04-23 2000-11-02 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic
IL155036A0 (en) 2000-09-26 2003-10-31 Reddy Research Foundation Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] benzyl] thiazolidine-2,4-dione maleate and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
NO20015149D0 (no) 2001-10-22
CA2370258A1 (en) 2000-11-02
WO2000064892A3 (en) 2001-01-25
AR023568A1 (es) 2002-09-04
BG106119A (en) 2002-05-31
OA11871A (en) 2006-03-27
KR20020028873A (ko) 2002-04-17
HK1045154A1 (en) 2002-11-15
CY1107238T1 (el) 2012-11-21
NZ515163A (en) 2004-02-27
DZ3155A1 (fr) 2000-11-02
ES2204557T3 (es) 2004-05-01
RS50114B (sr) 2009-03-25
DE60037602D1 (de) 2008-02-07
MA26785A1 (fr) 2004-12-20
AP1495A (en) 2005-11-30
EP1284268B1 (de) 2007-12-26
TW591027B (en) 2004-06-11
BR0009934A (pt) 2002-06-04
US6815457B1 (en) 2004-11-09
SK286423B6 (sk) 2008-09-05
US20040092555A1 (en) 2004-05-13
WO2000064892A2 (en) 2000-11-02
SK14912001A3 (sk) 2002-02-05
PT1173434E (pt) 2003-12-31
HK1055293A1 (en) 2004-01-02
PL351686A1 (en) 2003-06-02
HUP0200929A2 (en) 2002-08-28
CN1355801A (zh) 2002-06-26
DE60037602T2 (de) 2009-01-08
HRP20010773A2 (en) 2002-10-31
CZ20013799A3 (cs) 2002-04-17
DK1284268T3 (da) 2008-04-28
EP1284268A1 (de) 2003-02-19
UY26120A1 (es) 2000-12-29
CO5170424A1 (es) 2002-06-27
JP2002543075A (ja) 2002-12-17
CN1208335C (zh) 2005-06-29
EP1173434B1 (de) 2003-08-20
DE60004658D1 (de) 2003-09-25
ATE382046T1 (de) 2008-01-15
PE20010040A1 (es) 2001-03-10
AR023564A1 (es) 2002-09-04
EA004534B1 (ru) 2004-06-24
MXPA01010820A (es) 2002-06-04
AU4130600A (en) 2000-11-10
PT1284268E (pt) 2008-03-10
ES2298327T3 (es) 2008-05-16
IL146110A0 (en) 2002-07-25
EP1903043A1 (de) 2008-03-26
HUP0200929A3 (en) 2004-03-29
EA200101119A1 (ru) 2002-04-25
YU75201A (sh) 2004-09-03
TR200103061T2 (tr) 2002-05-21
ATE247653T1 (de) 2003-09-15
KR100744359B1 (ko) 2007-07-30
NO20015149L (no) 2001-12-17
EP1173434A2 (de) 2002-01-23
NO320589B1 (no) 2005-12-27
AU765498B2 (en) 2003-09-18
UA67843C2 (uk) 2004-07-15
HK1045154B (zh) 2004-06-25
HRP20010773B1 (en) 2005-06-30
BG65427B1 (bg) 2008-07-31
DE60004658T2 (de) 2004-06-24
MY128007A (en) 2007-01-31

Similar Documents

Publication Publication Date Title
DK1173434T3 (da) Thiazolidindionderivat og dets anvendelse som antidiabetisk middel
NO20020383L (no) Mutilinderivater og deres anvendelse som anti-bakterielle midler
NO20020683L (no) Arylmetyl karbonylamino tiazolderivater og deres anvendelse som antitumormidler
NO20021253L (no) Kinolylpropylpiperidinderivater og deres anvendelse som antibakterielle midler
DK1216247T3 (da) Imidazoimidazoler og triazoler som anti-inflammatoriske midler
NO20041560L (no) 1,6-nafthyridinderivater som antidiabetiske midler
DK1362027T3 (da) Acylerede 6,7,8,9-tetrahydro-5H-benzocycloheptenylaminer og deres anvendelse som farmaceutisk middel
NO20021408L (no) Oksa- og tiadiazol-derivater anvendelige som antidiabetiske og antiovervektsmidler
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
NL1016224A1 (nl) Foto-basevormend middel en foto-zuurvormend middel bevattende foto- etssamenstelling.
ZA200108718B (en) Thiazolidinedione derivative and its use as antidiabetic.
DK1464641T3 (da) 4-phenylpiperazinyl-, -piperidinyl- og -tetrahydropyridylderivater som dopamin-D4-antagonister
DK1231211T3 (da) Thiazolidindion-derivater som antidiabetika
DK1173437T3 (da) Thiazolidinindionderivat og dets anvendelse som antidiabetisk middel
NO20040702L (no) Kombinerte preparater som inneholder 1,4-benzotiepin-1,1-dioksidderivater og andre aktive substanser og anvendelsen derav
DK1173436T3 (da) Thiazolidindionderivat og anvendelse deraf som antidiabetikum
NO20030998L (no) Arylpiperazinderivater og deres anvendelse som psykotropiske midler
NO20021612L (no) Karbonylstressreduserende middel
ATE330603T1 (de) Benzothiazolderivaten
DK1325000T3 (da) Thiazoldiendionderivat og dets anvendelse som antidiabetisk middel
NO20035652D0 (no) Tiaziner og tiazoler som materialbeskyttelsesmidler
NO20015519D0 (no) Farmasöytisk sammensetning omfattende apokodein og/eller dets derivater
NO20005909D0 (no) Soppbasert middel samt fremstilling og anvendelse av dette
ES1049399Y (es) Figura articulada perfeccionada.
NO20014300D0 (no) Nytt protein og dets anvendelse